Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Harisios Tjionas, Amit K Gupta

Abstract

Carfilzomib is a proteasome inhibitor and immunomodulator used to treat patients with multiple myeloma who have disease progression refractory to bortezomib. The difference in agents is that carfilzomib is an irreversible inhibitor of 20 s proteasome. The most common side effects of carfilzomib are fatigue, nausea, diarrhea, anemia, thrombocytopenia, dyspnea, and pyrexia. Less frequent side effects include cardiac manifestations for which we will explore with more detail. In this case report, we describe a 70-year-old female with multiple myeloma presenting to the emergency department with complaint of dyspnea. Patient was discovered to be in heart failure with atrioventricular block necessitating placement of a pacemaker.

References

Dec 14, 2011·Emergency Medicine Australasia : EMA·Judith E Tintinalli
Jun 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas M HerndonRichard Pazdur
Aug 19, 2014·Antioxidants & Redox Signaling·Oliver Drews, Heinrich Taegtmeyer
Jan 13, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Juan TamargoEva Delpón
Feb 18, 2015·Current Cardiology Reports·Sachin Shah, Anju Nohria

❮ Previous
Next ❯

Citations

Oct 19, 2016·International Journal of Molecular Sciences·Khosrow Rezvani
Feb 22, 2018·Leukemia & Lymphoma·Chintan ShahJan S Moreb
Dec 6, 2018·Cardiovascular & Hematological Disorders Drug Targets·W SerraA Chetta
Jan 15, 2019·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Constantin A DasanuIon Codreanu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.